FTY720 inhibits tubulointerstitial inflammation in albumin overload-induced nephropathy of rats via the Sphk1 pathway
Abstract
Min XU, Dan LIU, Li-hong DING, Kun-ling MA, Min WU, Lin-li LV, Yi WEN, Hong LIU, Ri-ning TANG, Bi-cheng LIU*
Institute of Nephrology, Division of Nephrology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China
Aim: FTY720, a new immunomodulatory drug with low cytotoxicity, is currently used to treat multiple sclerosis. In this study, we investigated the effects of FTY720 on inflammatory cell infiltration in albumin overload-induced nephropathy of rats.
Methods: Male Wistar rats were subjected to right-side nephrectomy and divided into 3 groups. One week after the surgery, albumin overload (AO) group was treated with BSA (5 g·kg-1·d-1, ip) for 9 weeks; AO+FTY720 group was given BSA (5 g·kg-1·d-1, ip) plus FTY720 (0.5 g·-1·d-1, ip) for 9 weeks; and control group received daily ip injection of equivalent volume of saline. All rats were killed 9 weeks after nephrectomy.
Results: AO rats exhibited gradually increased urinary protein excretion accompanied by elevated urinary N-acetyl-β-O-glucosaminidase activity, and both reached their peak values at week 7. Furthermore, AO significantly increased lymphocytes and monocytes in circulation and the inflammatory cells recruited to tubulointerstitium, and the expression of inflammatory cytokines MCP-1, TNF-α and IL-6, as well as sphingosine 1-phosphate (S1P) receptors S1pr1 and S1pr3, and S1P-synthesizing enzyme sphingosine kinase 1 (Sphk1) in the kidney. Concomitant administration of FTY720 significantly attenuated all the AO-induced pathological changes.
Conclusion: FTY720 alleviates tubulointerstitium inflammation in an AO rat model of nephropathy via down-regulation of the Sphk1 pathwa
Keywords: FTY720; chronic kidney disease; nephropathy; albumin overload rat model; proteinuria; tubulointerstitium; inflammation; cytokine; Sphk1 pathway
This study was supported by grants from the Key Project of the National Natural Science Foundation of China (No 81130010), and Project of Jiangsu Clinical Medical Science (No BL2014080) to Prof Bi-cheng LIU.
* To whom correspondence should be addressed.
E-mail liubc64@163.com
Received 2014-05-05 Accepted 2014-09-05
Keywords:
Institute of Nephrology, Division of Nephrology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China
Aim: FTY720, a new immunomodulatory drug with low cytotoxicity, is currently used to treat multiple sclerosis. In this study, we investigated the effects of FTY720 on inflammatory cell infiltration in albumin overload-induced nephropathy of rats.
Methods: Male Wistar rats were subjected to right-side nephrectomy and divided into 3 groups. One week after the surgery, albumin overload (AO) group was treated with BSA (5 g·kg-1·d-1, ip) for 9 weeks; AO+FTY720 group was given BSA (5 g·kg-1·d-1, ip) plus FTY720 (0.5 g·-1·d-1, ip) for 9 weeks; and control group received daily ip injection of equivalent volume of saline. All rats were killed 9 weeks after nephrectomy.
Results: AO rats exhibited gradually increased urinary protein excretion accompanied by elevated urinary N-acetyl-β-O-glucosaminidase activity, and both reached their peak values at week 7. Furthermore, AO significantly increased lymphocytes and monocytes in circulation and the inflammatory cells recruited to tubulointerstitium, and the expression of inflammatory cytokines MCP-1, TNF-α and IL-6, as well as sphingosine 1-phosphate (S1P) receptors S1pr1 and S1pr3, and S1P-synthesizing enzyme sphingosine kinase 1 (Sphk1) in the kidney. Concomitant administration of FTY720 significantly attenuated all the AO-induced pathological changes.
Conclusion: FTY720 alleviates tubulointerstitium inflammation in an AO rat model of nephropathy via down-regulation of the Sphk1 pathwa
Keywords: FTY720; chronic kidney disease; nephropathy; albumin overload rat model; proteinuria; tubulointerstitium; inflammation; cytokine; Sphk1 pathway
This study was supported by grants from the Key Project of the National Natural Science Foundation of China (No 81130010), and Project of Jiangsu Clinical Medical Science (No BL2014080) to Prof Bi-cheng LIU.
* To whom correspondence should be addressed.
E-mail liubc64@163.com
Received 2014-05-05 Accepted 2014-09-05